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During our investigations of protein kinase inhibitors, 1,2 we became interested in BAY 61-3606 (1), which is an ATPcompetitive, reversible, selective protein kinase inhibitor. It was originally employed as a potent, orally available spleen tyrosine kinase (Syk) inhibitor. 3 It was reported to attenuate the proliferation of retinoblastoma cells 4 and B-cell leukemia cells, 5 and has been utilized to examine chemomigration of nasopharyngeal carcinoma cells. 6 A pre-clinical study showed that BAY 61-3606 also reduces the viability of colon cancer cells by inhibiting germinal center kinase (Gck, MAP4K2), 7 a member of the serine/threonine protein kinase family. Although the biological functions of Gck are not yet well understood, it may work as a regulator of NFκβ to modulate UV-induced apoptosis of melanoma cells. 8 To investigate the biological functions of Gck in detail, selective inhibitors of Gck are required.
Here, we focused on BAY 61-3606 (1) as a lead compound for selective Gck inhibitors. Generally, the hinge region, DFG loop, gatekeeper residue and hydrophobic pocket of protein kinases are essential features of the binding sites of most ATPcompetitive protein kinase inhibitors. 9 However, the binding modes of 1 to Syk and Gck are unknown. Therefore, we set out to synthesize a series of inhibitor candidates and to explore their structure-activity relationships towards these kinases. We planned to develop two synthetic strategies, one for modification of the substituted benzene moiety at the 7-position and the other We first explored replacement of the dimethoxybenzene moiety in BAY 61-3606, as shown in Scheme 2. The imidazo[1,2-c]pyrimidine skeleton of 3 was constructed by condensation of tri-substituted pyrimidine 2 with bromoacetaldehyde dimethyl acetal. 10 After hydrolysis of the thiomethyl group, chloridation of the resulting hydroxy group furnished 5,7-dichloroimidazo[1,2-c]pyrimidine (4) . While aniline derivatives could be reacted with 4 at the 5-position by means of Haigis' method 7 that heating with 4 and anilines in solvent, the amino-nicotinic ester could not be incorporated. To obtain the desired common intermediate 5, treatment of 4 with 2-amino-3-methoxycarbonylpyridine under basic conditions was adopted, affording 5 in 80% yield. Although the palladiumcatalyzed amination of 4 also proceeded, the chemical yield of 5 was relatively low (data not shown). For the preparation of 1, microwave-assisted Suzuki-Miyaura coupling reaction with 3,4-dimethoxyphenylboronic acid was employed to obtain 6. Finally, ammonolysis of 6 gave the desired 1 in 12% yield over 2 steps. This protocol was utilized for the preparation of several derivatives 7a-o. 11, 12 of 10a and 2-bromopyridine derivative provided the BAY 61-3606 framework 11a. Ammonolysis of 11a proceeded with several amines to give amide derivatives 7p-x. Since Pd-mediated cross-coupling reactions can proceed with various aromatic halides, this protocol should be also applicable to generate diverse BAY 61-3606 analogues. Employment of m-BrBzCl with 8 provided 10b via a procedure similar to that used to prepare 10a. Bromide 10b can undergo additional cross-coupling reaction, and Suzuki-Miyaura coupling of 10b with p-methoxyphenylboric acid provided 10c. Subsequently, ammonolysis of 10c also proceeded smoothly to give 7y.
Although the synthetic method illustrated in
Next we turned our attention to replacement of the core skeleton of 1 from the imidazo[1,2-c]pyrimidine ring to an indole. Since many drugs contain indole structures, development of a versatile synthetic method would be potentially valuable. Thus, we planned to construct a platform strategy for the synthesis of indole derivatives as shown in Scheme 4. After regioselective bromination of 2,6-dinitrotoluene (12), indole structure was constructed by employing the Leimgruber and Batcho protocol. 13, 14 Following treatment of 4-bromo-2,6-dinitrotoluene (13) with DMF dimethylacetal and pyrrolidine, the desired alkylation reaction of 13 proceeded smoothly. Subsequently, TiCl 3 mediated mono-selective reduction of the nitro group afforded the stable 6-bromo-4-nitroindole 14. The indole 14 served as a platform for subsequent stepwise cross-coupling reactions. Firstly, incorporation of an aromatic ring was performed by Suzuki-Miyaura coupling reaction. After reduction of the nitro group of 15, amination reaction under similar conditions to those employed in the synthesis of imidazopyrimidine derivatives in Scheme 2 gave 17. Since conversion of the aniline group to diazonium salt and subsequent cross coupling reaction could be readily carried out, 16a, b were also considered to be available as coupling precursors. We next evaluated the Syk-and Gck-inhibitory activities of the synthesized BAY 61-3606 derivatives (Table 1) . Specifically, we compared the ability of BAY 61-3606 derivatives at the concentration of 1 µM to competitively inhibit binding of ATP to the active sites of these kinases. BAY 61-3606 (1) showed 85% inhibition of Syk activity and 100% inhibition of Gck activity. In addition, potent inhibition of both Syk and Gck was observed by 7a, 7c, 7e, 7f, 7j, and 7k. It is noteworthy that 7p, which does not possess any substitution on the phenyl group at the 7-position of imidazo[1,2-c]pyrimidine, also showed potent inhibition of both kinases. Potent and selective Gck-inhibitory activity was observed with several other derivatives (7b; R = 3-OMe, 7d; R = 3,4-dioxole, 7i; R = 2-Me, 7y; R = 3-(pMeO-C 6 H 4 )). Furthermore, the concentration dependency of the activity of these 4 compounds were measured, and K d s were determined to be 59, 49, 100 and 220 nM, respectively. These results suggest that a benzene moiety with these R groups is important for the kinaseinhibitory activity. Introduction of a methyl group at the amide moiety, the resulting 7l-7o caused marked attenuation of the inhibitory activities towards both Gck and Syk. In derivatives that having various alkylamides, 7q-7x, the inhibitory activities were completely abrogated. It is suspected that the amide moiety also plays a critical role in the interaction with both kinases. Indole derivative 17a showed selective Gck inhibition, although the activity was weak. Since 17a had decreased Syk-inhibitory activity compared to 7q, the indole skeleton may play an important role in selective kinase inhibition. Since addition of the bulky p-methoxyphenyl group in the phenyl imidazo[1,2-c]pyrimidine ring, such as 7y, did not decrease the biological activity, this compound may be available as a probe molecule for chemical biology studies. We have previously accomplished the synthesis of several probe molecules by elongation and addition of aromatic rings to active compounds together with the use of a linker group and probe unit such as biotin and/or a fluorescent group. [15] [16] [17] [18] Further investigations to develop a probe molecule from 7y are currently underway in our laboratory.
In summary, we have developed novel divergent synthetic routes to various imidazo[1,2-c]pyrimidine and indole derivatives related to BAY 61-3606. Among them 7b, 7d, 7i, and 7y exhibited selective Gck inhibition. They may be suitable for the development of probes for studying the biological roles of Gck.
